# XALience (NCT07213674)

> A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07213674
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Amgen
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: Xaluritamig; Abiraterone acetate; Docetaxel; Cabazitaxel
- Enrollment: 750
- Primary outcome: OS

## Indexed commentary on XALience so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=xalience-nct07213674